- cafead   Apr 05, 2022 at 11:32: PM
via Coming off a strong year of growth for its Eli Lilly-partnered SGLT2 inhibitor Jardiance, Boehringer Ingelheim is putting those gains right back into R&D — and setting some lofty goals for the next few years.
article source
article source